Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
CNS Drugs. 2014 Jul;28(7):601-9. doi: 10.1007/s40263-014-0171-5.
Studies have found that up to two-thirds of patients with major depressive disorder (MDD) do not fully respond to the first antidepressant. While switching antidepressants is a common strategy for antidepressant non-responders, there is still a lack of consensus about the optimal timing of a switch. Many clinicians wait for 6-12 weeks before considering a switch. The objectives of this paper are to (1) review the evidence for positive and negative predictive value (NPV) of early improvement at 2-4 weeks to predict final antidepressant response; (2) review randomized controlled trials (RCTs) that examine early switching strategies; and (3) provide future research directions and clinical recommendations for timing of antidepressant switching. We conducted a literature search for English-language studies via PubMed and Google Scholar, from 1984 to May 2013, with the following terms: 'antidepressants', 'MDD', 'time course', 'trajectory', 'early response', 'onset', 'delayed response', 'early improvement', 'predictors', 'switch', 'combination therapy', and 'augmentation'. Replicated evidence indicates that lack of early improvement (e.g. <20% reduction in a depression scale score) at 2-4 weeks can be an accurate predictor to identify eventual non-responders. The NPVs suggest that only about one in five patients with lack of improvement at 4 weeks will have a response by 8 weeks. Three RCTs examined early switch strategies, but results are inconsistent and comparisons limited by methodological differences. Future studies should incorporate a standard consensus definition of early improvement, discern whether the effect of early switching is specific to certain types of antidepressants, and determine whether early switch is superior to other strategies such as augmentation or combination. Notwithstanding these limitations, there is reasonable evidence to recommend earlier assessment for improvement. If there is no indication of early improvement at 2-4 weeks after starting an antidepressant, and taking into account other patient and clinical factors, a change in management can be considered.
研究发现,多达三分之二的重度抑郁症(MDD)患者对第一种抗抑郁药没有完全反应。虽然转换抗抑郁药是抗抑郁药无反应者的常见策略,但对于转换的最佳时机仍缺乏共识。许多临床医生在考虑转换之前等待 6-12 周。本文的目的是:(1)回顾 2-4 周早期改善对最终抗抑郁反应的阳性和阴性预测值(NPV)的证据;(2)回顾检查早期转换策略的随机对照试验(RCT);(3)为抗抑郁药转换的时机提供未来的研究方向和临床建议。我们通过 PubMed 和 Google Scholar 进行了英语文献搜索,检索时间为 1984 年至 2013 年 5 月,使用的术语包括:“抗抑郁药”、“MDD”、“时间进程”、“轨迹”、“早期反应”、“发作”、“延迟反应”、“早期改善”、“预测因子”、“转换”、“联合治疗”和“增效”。重复的证据表明,2-4 周时缺乏早期改善(例如,抑郁量表评分降低<20%)可以准确预测最终无反应者。NPV 表明,在 4 周时无改善的患者中,只有约五分之一的患者在 8 周时会有反应。三项 RCT 检查了早期转换策略,但结果不一致,比较受到方法学差异的限制。未来的研究应纳入早期改善的标准共识定义,区分早期转换的效果是否特定于某些类型的抗抑郁药,并确定早期转换是否优于其他策略,如增效或联合治疗。尽管存在这些局限性,但有合理的证据推荐更早进行改善评估。如果在开始抗抑郁药后 2-4 周没有早期改善的迹象,并考虑到其他患者和临床因素,可以考虑改变治疗方案。